Leukotriene B4 (LTB4) receptor type 2 (BLT2) is a G protein–coupled receptor (GPCR) for
12(S)-hydroxyheptadeca-5Z,8E,10E-trienoic acid (12-HHT) and LTB4. Despite the welldefined
proinflammatory roles of BLT1, the in vivo functions of BLT2 remain elusive. As
mouse BLT2 is highly expressed in epidermal keratinocytes, we investigated the role of the
12-HHT/BLT2 axis in skin wound healing processes. 12-HHT accumulated in the wound fluid
in mice, and BLT2-deficient mice exhibited impaired re-epithelialization and delayed wound
closure after skin punching. Aspirin administration reduced 12-HHT production and resulted
in delayed wound closure in wild-type mice, which was abrogated in BLT2-deficient mice.
In vitro scratch assay using primary keratinocytes and a keratinocyte cell line also showed that
the 12-HHT/BLT2 axis accelerated wound closure through the production of tumor necrosis
factor (TNF) and matrix metalloproteinases (MMPs). A synthetic BLT2 agonist accelerated
wound closure in cultured cells as well as in C57BL/6J and diabetic mice. These results
identify a novel mechanism underlying the action of the 12-HHT/BLT2 axis in epidermal
keratinocytes and accordingly suggest the use of BLT2 agonists as therapeutic agents to
accelerate wound healing, particularly for intractable wounds, such as diabetic ulcers.